These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3926333)

  • 1. The treatment of postmenopausal women with advanced breast cancer with buserelin.
    Waxman JH; Harland SJ; Coombes RC; Wrigley PF; Malpas JS; Powles T; Lister TA
    Cancer Chemother Pharmacol; 1985; 15(2):171-3. PubMed ID: 3926333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Buserelin therapy in postmenopausal patients with advanced breast carcinoma].
    Vici P; Veltri E; Carpano S; Di Lauro L; Lopez M
    Clin Ter; 1991 Feb; 136(3):195-9. PubMed ID: 1827382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced prostatic cancer with buserelin, an analogue of gonadotrophin releasing hormone.
    Waxman JH; Wass JA; Hendry WF; Whitfield HN; Bary P; Besser GM; Malpas JS; Oliver RT
    Br J Urol; 1983 Dec; 55(6):737-42. PubMed ID: 6418264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrinology of Zoladex in postmenopausal women.
    Dowsett M; Cantwell BM; Harris AL
    Horm Res; 1989; 32 Suppl 1():209-12. PubMed ID: 2533152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630.
    Plowman PN; Nicholson RI; Walker KJ
    Br J Cancer; 1986 Dec; 54(6):903-9. PubMed ID: 2948537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and endocrine effects of leuprorelin acetate in pre- and postmenopausal patients with advanced breast cancer.
    Dowsett M; Jacobs S; Aherne J; Smith IE
    Clin Ther; 1992; 14 Suppl A():97-103. PubMed ID: 1606596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.
    Waxman JH; Wass JA; Hendry WF; Whitfield HN; Besser GM; Malpas JS; Oliver RT
    Br Med J (Clin Res Ed); 1983 Apr; 286(6374):1309-12. PubMed ID: 6404441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic use of a gonadotropin releasing hormone analogue in breast cancer].
    Kahán Z; Falkay G
    Orv Hetil; 1990 May; 131(19):1033-6. PubMed ID: 2111904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A long term follow-up of patients with advanced prostatic cancer treated with buserelin.
    Waxman JH; Hendry WF; Whitfield HN; Oliver RT
    Prog Clin Biol Res; 1985; 185A():271-7. PubMed ID: 3929266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary endocrinological evaluation of a sustained-release formulation of the LH-releasing hormone agonist D-Ser(But)6Azgly10LHRH in premenopausal women with advanced breast cancer.
    Walker KJ; Turkes A; Williams MR; Blamey RW; Nicholson RI
    J Endocrinol; 1986 Nov; 111(2):349-53. PubMed ID: 2947964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.
    Brogden RN; Buckley MM; Ward A
    Drugs; 1990 Mar; 39(3):399-437. PubMed ID: 2109679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist goserelin.
    Dowsett M; Cantwell B; Lal A; Jeffcoate SL; Harris AL
    J Clin Endocrinol Metab; 1988 Apr; 66(4):672-7. PubMed ID: 2964454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study.
    Klijn JG; Beex LV; Mauriac L; van Zijl JA; Veyret C; Wildiers J; Jassem J; Piccart M; Burghouts J; Becquart D; Seynaeve C; Mignolet F; Duchateau L
    J Natl Cancer Inst; 2000 Jun; 92(11):903-11. PubMed ID: 10841825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of the endocrine actions of luteinising hormone-releasing hormone analogues in premenopausal women with breast cancer.
    Nicholson RI; Walker KJ; Walker RF; Read GF; Turkes A; Robertson JF; Blamey RW
    Horm Res; 1989; 32 Suppl 1():198-201. PubMed ID: 2533149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer.
    Nicholson RI; Walker KJ; Turkes A; Dyas J; Plowman PN; Williams M; Blamey RW
    J Steroid Biochem; 1985 Nov; 23(5B):843-7. PubMed ID: 2934580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.
    Kaufmann M; Jonat W; Kleeberg U; Eiermann W; Jänicke F; Hilfrich J; Kreienberg R; Albrecht M; Weitzel HK; Schmid H
    J Clin Oncol; 1989 Aug; 7(8):1113-9. PubMed ID: 2526863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LHRH-agonist treatment in clinical and experimental human breast cancer.
    Klijn JG; de Jong FH; Lamberts SW; Blankenstein MA
    J Steroid Biochem; 1985 Nov; 23(5B):867-73. PubMed ID: 3935869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic effects of the stimulatory luteinizing hormone-releasing hormone analogue D-Ser (TBU) 6-EA 10-LRH on the gonadotrophin and gonadal steroid secretion in women with amenorrhoea.
    Skarin G; Nillius SJ; Wide L
    Ups J Med Sci; 1980; 85(2):103-12. PubMed ID: 6787767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of chemotherapy with or without buserelin on serum hormone levels in premenopausal women with breast cancer.
    Falkson CI; Falkson HC; Falkson G
    Eur J Cancer; 1991; 27(10):1208-11. PubMed ID: 1835587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of breast cancer with gonadotropin-releasing hormone.
    Manni A; Santen R; Harvey H; Lipton A; Max D
    Endocr Rev; 1986 Feb; 7(1):89-94. PubMed ID: 3082618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.